[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 892 Introduced in Senate (IS)]
<DOC>
118th CONGRESS
1st Session
S. 892
To amend title XVIII of the Social Security Act to provide coverage
under the Medicare program for FDA-approved qualifying colorectal
cancer screening blood-based tests, to increase participation in
colorectal cancer screening in under-screened communities of color, to
offset the COVID-19 pandemic driven declines in colorectal cancer
screening, and for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
March 21, 2023
Mr. Heinrich introduced the following bill; which was read twice and
referred to the Committee on Finance
_______________________________________________________________________
A BILL
To amend title XVIII of the Social Security Act to provide coverage
under the Medicare program for FDA-approved qualifying colorectal
cancer screening blood-based tests, to increase participation in
colorectal cancer screening in under-screened communities of color, to
offset the COVID-19 pandemic driven declines in colorectal cancer
screening, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Colorectal Cancer Detection Act''.
SEC. 2. MEDICARE COVERAGE FOR FDA-APPROVED QUALIFYING COLORECTAL CANCER
SCREENING BLOOD-BASED TESTS.
(a) In General.--Section 1861(pp) of the Social Security Act (42
U.S.C. 1395x(pp)) is amended--
(1) in paragraph (1)--
(A) by redesignating subparagraph (D) as
subparagraph (E); and
(B) by inserting after subparagraph (C) the
following new subparagraph:
``(D) Qualifying colorectal cancer screening blood-based
test.''; and
(2) by adding at the end the following new paragraph:
``(3) The term `qualifying colorectal cancer screening blood-based
test' means a screening blood-based test for the early detection of
colorectal cancer that is marketed or used, as applicable, in
accordance with the relevant provisions of section 353 of the Public
Health Service Act or the Federal Food, Drug, and Cosmetic Act.''.
(b) Frequency Limits for Colorectal Cancer Screening Tests and
Payment Amount for Qualifying Colorectal Cancer Screening Blood-Based
Tests.--Section 1834(d) of the Social Security Act (42 U.S.C. 1395m(d))
is amended--
(1) by amending clause (ii) of paragraph (1)(B) to read as
follows:
``(ii) if the test is performed within the
11 months after a previous screening fecal-
occult blood test or a previous qualifying
colorectal cancer screening blood-based
test.'';
(2) in paragraph (2)(E)(ii), by inserting ``or within the
35 months after a previous screening fecal-occult blood test or
previous qualifying colorectal cancer screening blood-based
test'' after ``sigmoidoscopy'';
(3) by amending subparagraph (E) of paragraph (3) to read
as follows:
``(E) Frequency limit.--No payment may be made
under this part for a colorectal cancer screening test
consisting of a screening colonoscopy--
``(i) if the procedure is performed within
the 11 months after a previous screening fecal-
occult blood test or previous qualifying
colorectal cancer screening blood-based test;
``(ii) for individuals at high risk for
colorectal cancer if the procedure is performed
within the 23 months after a previous screening
colonoscopy; or
``(iii) for individuals not at high risk
for colorectal cancer if the procedure is
performed within the 119 months after a
previous screening colonoscopy or within the 47
months after a previous screening flexible
sigmoidoscopy.''; and
(4) by adding at the end the following new paragraph:
``(4) Qualifying colorectal cancer screening blood-based
tests.--
``(A) Payment amount.--The payment amount for
colorectal cancer screening tests consisting of
qualifying colorectal cancer screening blood-based
tests shall be established by the Secretary in
accordance with section 1833(h) and section 1834A, as
applicable.
``(B) Frequency limit.--Paragraph (1)(B) shall
apply to colorectal cancer screening tests consisting
of qualifying colorectal cancer screening blood-based
tests in the same manner as such paragraph applies to
colorectal cancer screening tests consisting of fecal-
occult blood tests.''.
(c) Effective Date.--The amendments made by this section shall
apply to colorectal cancer screening tests furnished in a year
beginning more than 6 months after the date of the enactment of this
Act.
<all>